Jacob P. Laubach
Expertise in
14
conditions

Dr. Jacob P. Laubach

Oncology | Hematology
450 Brookline Avenue, 
Boston, MA 
Offers Telehealth
Expertise in
14
conditions
450 Brookline Avenue, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jacob Laubach is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Laubach is highly rated in 14 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 181 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Duke University School Of Medicine, 1999
Residency
Duke University Medical Center-GME, 2002
Specialties
Oncology
Hematology
Licenses
Internal Medicine in NC
Board Certifications
Hematology
Internal Medicine
Medical Oncology
Fellowships
Duke University Medical Center-GME, 2008
Hospital Affiliations
Massachusetts General Hospital
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Community Health Options
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
450 Brookline Avenue, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 2
Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: ACE-011, Lenalidomide, Dexamethasone, Pomalidomide
Study Phase: Phase 1
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug, Procedure
Study Drugs: Bortezomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drugs: Ibrutinib, Lenalidomide, Dexamethasone
Study Phase: Phase 1
Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drugs: Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone
Study Phase: Phase 2
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drugs: Panobinostat Capsules, Bortezomib Injection, Dexamethasone Tablets
Study Phase: Phase 2
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 05, 2021
Intervention Type: Drug
Study Drugs: Panobinostat, Dexamethasone, Lenalidomide, Bortezomib
Study Phase: Phase 1
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: November 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Enrollment Status: Withdrawn
Publish Date: August 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Enrollment Status: Completed
Publish Date: March 16, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 9 Less Clinical Trials

181 Total Publications

Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Journal: Expert opinion on emerging drugs
Published: October 30, 2025
Similar Doctors
Expertise in
11
conditions
Dr. Steven Dubois
Hematology | Oncology
Expertise in
11
conditions
Dr. Steven Dubois
Hematology | Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances

Steven Dubois is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Dubois is highly rated in 11 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma.

Expertise in
14
conditions
Dr. Matthew Heeney
Hematology | Oncology
Expertise in
14
conditions
Dr. Matthew Heeney
Hematology | Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances

Matthew Heeney is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Heeney is highly rated in 14 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

Expertise in
15
conditions
Dr. Andrew Yee
Hematology | Oncology
Expertise in
15
conditions
Dr. Andrew Yee
Hematology | Oncology

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Yee is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Yee is highly rated in 15 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Vertebroplasty, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Laubach's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile